SEC Tracker
Get the app

Nutra Pharma NPHC

Nutra Pharma Q1 FY25: revenue $74K, up 96%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Nutra Pharma reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$74K+96% from $38K in Q1 FY2410-Q income statement, on EDGAR
  2. Net income−$1.4MAgainst −$427K in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.00Against $0.00 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$14KAgainst $0 in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$405KAgainst −$171K in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Nutra Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.